These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials. Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011 [TBL] [Abstract][Full Text] [Related]
7. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach. Bukowski RM Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712 [TBL] [Abstract][Full Text] [Related]
8. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394 [TBL] [Abstract][Full Text] [Related]
10. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Keisner SV; Shah SR Drugs; 2011 Mar; 71(4):443-54. PubMed ID: 21395357 [TBL] [Abstract][Full Text] [Related]
12. Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis. Ravasio R; Ortega C; Sabbatini R; Porta C Clin Drug Investig; 2011; 31(7):507-17. PubMed ID: 21627339 [TBL] [Abstract][Full Text] [Related]
13. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442 [TBL] [Abstract][Full Text] [Related]
14. Treatment of metastatic renal cell carcinoma. Reeves DJ; Liu CY Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348 [TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. Albiges L; Salem M; Rini B; Escudier B Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969 [TBL] [Abstract][Full Text] [Related]
16. Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data. McDermott DF; George DJ Cancer Treat Rev; 2010 May; 36(3):216-23. PubMed ID: 20116176 [TBL] [Abstract][Full Text] [Related]
17. Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study. Martín-Aguilar AE; Núñez-López H; Ramirez-Sandoval JC BMC Cancer; 2021 Jan; 21(1):16. PubMed ID: 33402115 [TBL] [Abstract][Full Text] [Related]
18. The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study. Bamias A; Karavasilis V; Gavalas N; Tzannis K; Samantas E; Aravantinos G; Koutras A; Gkerzelis I; Kostouros E; Koutsoukos K; Zagouri F; Fountzilas G; Dimopoulos MA Int J Clin Oncol; 2019 Apr; 24(4):411-419. PubMed ID: 30374686 [TBL] [Abstract][Full Text] [Related]
19. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Sosman JA; Puzanov I; Atkins MB Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307 [TBL] [Abstract][Full Text] [Related]
20. Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress? Rini BI; Bukowski RM Oncology (Williston Park); 2008 Apr; 22(4):388-96; discussion 396, 402-3, 476 passim. PubMed ID: 18472614 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]